RAPIDE: The Feasibility of a Hybrid Care Model
NCT06735404 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180
Last updated 2025-09-12
Summary
Rationale: During cross-border health emergencies, such as seen with the COVID-19 pandemic, health and care services are rapidly being overwhelmed by high numbers of patients requiring care, leading to stretches in the whole healthcare system. Delays and backlogs in regular care, as the result of the stretched health care services, leave millions of patients with regular care needs unattended, resulting in disastrous healthcare outcomes. If disastrous healthcare outcomes across the population are to be avoided, healthcare systems must become more robust, resilient, and flexible in the face of future health emergencies and allow for rapid changes in the care delivery services.
Objective: To evaluate the feasibility of delivering a hybrid care model alongside care as usual through observations, and questionnaires and interviews on patient reported views, opinions, and experiences. This hybrid care model aims to reduce the burden on health and care systems during a health emergency, decrease the need to scale down regular care, and ensure patient safety and quality of care.
Study design: One year cohort study, using observations, questionnaires, and interviews.
Study population: Patients with type 2 diabetes and/or chronic heart failure with comorbidities and/or having a high care consumption according to the treating general practitioner.
Intervention: The hybrid care model will consist of a combination of digital tools and/or task shifting of certain healthcare providers. Examples are:
* Telemonitoring: patients perform self-measurements through e.g. sensors, wearables, or (mobile) applications to get insight in their health status (supporting self-management) and report this to their healthcare provider(s), when relevant
* Teleconsultation: patients communicate with their healthcare provider(s) remotely
* Personal health portals and self-management applications
* Online prescription requests: patients request prescription online Main study parameters/endpoints: The impact of the hybrid care model on patient reported experiences (PREMs) and patient reported outcomes (PROMs).
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Evaluating the feasibility of this hybrid care model will only be done through observations, questionnaires, and interviews at home (during three home visits at baseline, after six months, and after one year). No invasive (physical) procedures will be performed.
Conditions
- Diabetes Type 2
- Heart Failure
Interventions
- OTHER
-
Hybrid care
The hybrid care model will consist of a combination of digital tools and/or task shifting of certain healthcare providers. Examples are: * Telemonitoring: patients perform self-measurements through e.g. sensors, wearables, or (mobile) applications to get insight in their health status (supporting self-management) and report this to their healthcare provider(s), when relevant * Teleconsultation: patients communicate with their healthcare provider(s) remotely * Personal health portals and self-management applications * Online prescription requests: patients request prescription online
Sponsors & Collaborators
-
Radboud University Medical Center
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-01-31
- Primary Completion
- 2027-03-31
- Completion
- 2027-03-31
Countries
- Italy
- Malta
- Netherlands
- Slovenia
Study Locations
More Related Trials
-
Regadenoson and Adenosine
NCT01809743 ·Status: COMPLETED ·Phase: PHASE3
-
Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List
NCT04782245 ·Status: WITHDRAWN ·Phase: PHASE2
-
Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
NCT00585546 ·Status: TERMINATED ·Phase: PHASE1
-
Dopamine in Acute Decompensated Heart Failure II
NCT01060293 ·Status: TERMINATED ·Phase: PHASE4
-
Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients
NCT00562952 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
NCT04988386 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients
NCT06535529 ·Status: RECRUITING ·Phase: PHASE3
-
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362 ·Status: RECRUITING ·Phase: PHASE2
-
Empagliflozin in Hypertrophic Cardiomyopathy
NCT05182658 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
NCT02653482 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients
NCT00655538 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics of Bisoprolol and SGLT2i in Acutely Decompensated Heart Failure
NCT06453577 ·Status: ACTIVE_NOT_RECRUITING
-
Diabetic Autonomic Neuropathy and Left Ventricular Function
NCT05713396 ·Status: COMPLETED ·Phase: PHASE4
-
Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD
NCT03593317 ·Status: RECRUITING ·Phase: PHASE2
-
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
NCT06215586 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461
NCT02329184 ·Status: COMPLETED ·Phase: PHASE1
-
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
NCT05318105 ·Status: RECRUITING ·Phase: NA
-
Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients With Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial Fibrillation
NCT02764619 ·Status: UNKNOWN ·Phase: PHASE3
-
Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure
NCT05093621 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
NCT06005428 ·Status: TERMINATED ·Phase: PHASE2
-
Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure
NCT01644331 ·Status: COMPLETED ·Phase: PHASE3
-
Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure
NCT06783166 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
NCT04363697 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
NCT05350969 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.
NCT00353522 ·Status: COMPLETED ·Phase: PHASE2